Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Therapeutic Potential of Newer Drugs for Treating Hyperkalemia

Matthew R. Weir
CJASN June 2019, 14 (6) 787-788; DOI: https://doi.org/10.2215/CJN.04750419
Matthew R. Weir
Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • hyperkalemia
  • chronic kidney disease
  • renin angiotensin aldosterone-system inhibitors
  • Potassium
  • risk factors

Hyperkalemia is a potentially serious medical condition that can result in cardiac arrhythmia and sudden death. It is more commonly seen in patients who are older, have CKD, have diabetes, or are receiving renin-angiotensin aldosterone-system inhibitors (RAASis). The problem is frequent in clinical practice and often leads to increased use of health care resources. An episode of hyperkalemia in hospitalized patients with or without CKD increases the odds of mortality within 1 day of the event (1). RAASis are some of the most important therapies to use in patients with CKD and/or cardiovascular disease. RAASis are either underdosed or stopped in patients who develop hyperkalemia. Although there are a number of effective therapeutic options for the acute management of chronic hyperkalemia, opportunities to provide safe, effective, and well tolerated management of chronic hyperkalemia are limited. Traditionally, health care providers focus on diet, although there are limited data to suggest that dietary modification chronically controls hyperkalemia over the long-term in patients with CKD (2). Intensified use of diuretics (especially loop diuretics), reduction or cessation of RAASi, or intermittent use of sodium polystyrene sulfonate are other strategies. The latter drug has been in use for many decades. Yet, because of its foul taste and consistency and the potential risk for colonic injury (3), it has not been demonstrated to be an effective approach in long-term clinical studies to manage chronic hyperkalemia.

Over the last few years, two new potassium binding therapies have been in development. In 2015, the Food and Drug Administration (FDA) approved patiromer, a polymer that exchanges calcium for potassium, as a chronic treatment for hyperkalemia (4). In the past year, the FDA has approved sodium zirconium cyclosilicate (SZC) for management of hyperkalemia. The report by Spinowitz et al. (5) is important, because it provides 1-year data on the use of this drug to control hyperkalemia in a group of participants who are hyperkalemic, many of whom had an eGFR below 60 ml/1.73 m2. Many patients (65%) were also taking RAASis. The main strength of the paper is the large number of participants (n=745) and the 1-year duration of treatment. The only weakness is the lack of a placebo group to provide contrast with the treatment group with regard to adverse events. Overall, the SZC therapy was well tolerated, and it was simply administered as a once a day medication dissolved in a small amount of water, preferably taken separately from other medications by at least 2 hours. Side effects likely related to the medication included constipation (6%), hypertension (11%), and peripheral edema (10%). However, the latter two side effects are often seen in patients with CKD and may not necessarily be related to the therapy. It should be noted, however, that sodium is exchanged for potassium with this medication, which could potentially explain some of the observations, especially if higher doses are used. During the study, the serum potassium was maintained at ≤5.1 mEq/L in 88% of participants and ≤5.5 mEq/L in 99% of participants. Perhaps the most important observations in the study were that, of the 483 hyperkalemic RAASi users at baseline, 87% continued on therapy or had their dose increased, and only 11% of patients had RAASis discontinued. Among 263 RAASi-naïve participants, 14% were initiated on RAASi therapy.

Given that both patiromer and SZC are simply administered, well tolerated, safe, and effective, health care providers now have two viable choices to consider for long-term management of hyperkalemia. This leads to an important question: is it possible now to safely enable optimal RAASi (evidenced-based dosing) in patients who have been previously untreated, dose reduced, or stopped in the past. As such, these new potassium binders may be more than a treatment for hyperkalemia but a means for facilitating RAASi in patients with kidney and/or cardiovascular disease. Health care providers are well aware of evidence-based treatment recommendations for RAASis in patients with proteinuric diabetic kidney disease (6,7). Only full therapeutic doses of RAASi have been demonstrated to being effective in providing a 20% relative risk reduction benefit on the progression of established CKD to an end point of doubling of creatinine, ESKD, or death (6,7). Yet, the vast majority of patients with diabetic kidney disease, especially if it is more advanced, either are not on RAASis or are on much lower doses, which have been demonstrated to be beneficial in protecting and stabilizing kidney function. Likewise, patients with systolic heart failure, especially if they have reduced kidney function or cardiorenal syndrome, often are underdosed with RAASis. In addition, patients with congestive heart failure often do not receive mineralocorticoid receptor antagonists, despite the benefit of these drugs for reducing morbidity and mortality in patients with congestive heart failure (8). Interestingly, patients with congestive heart failure treated with mineralocorticoid receptor antagonists derive mortality benefit even in the presence of higher serum potassium levels (9).

From a pragmatic standpoint, enabling RAASi sounds so simple. Yet, it does require more effort on part of the health care provider to carefully monitor the patient, encourage adherence and insist that the patient return for follow-up laboratory appointments. Despite the increased work load, the long-term benefits for the patient could be substantial.

Given the cost of these new therapies, studies need to be designed to demonstrate the utility of RAASi enabling in patients with CKD, congestive heart failure, or both. This would provide an opportunity to examine the value of controlling hyperkalemia and maintaining evidence-based doses of RAASi, mineralocorticoids receptor antagonists, or both. A study conducted in patients with congestive heart failure demonstrated the short-term benefits of using a potassium-binding therapy with patiromer in enabling and maintaining spironolactone therapy over a period of 4 weeks (10). However, this pilot study was not of sufficient duration to allow an assessment on mortality. Consequently, longer-term studies are needed to demonstrate that RAASi enabling does provide a demonstrable clinical benefit.

From a safety standpoint, it may be more practical to use a potassium binder rather than increase the dose of loop diuretics to control hyperkalemia. This could lead to volume depletion and worsening azotemia in patients with CKD or hypotension and AKI in patients with congestive heart failure. Additionally, in one study with placebo-controlled withdrawal of the potassium binder patiromer, there was no evidence of a rapid return of hyperkalemia after cessation of the potassium binder. The slow return of serum potassium to baseline is important and indicates no evidence of a quick rebound.

Thus, if there is an unanticipated cessation of therapy or nonadherence sufficient homeostatic mechanisms are in place to avoid abrupt changes in serum potassium, which could be life threatening.

There are some minor obstacles, however, with these newer therapies. The potassium binders need to be separated from other medications (for 2 hours for SZC and for 3 hours for patiromer) due to the potential of binding other drugs. However, this is a minor inconvenience relative to the opportunity to maintain RAASi. Incidentally, all of the development studies with these drugs were done without any separation from other medications, and there was no clinical evidence of an interaction.

The introduction of safe, effective, and well tolerated potassium binders is not simply a measure to treat hyperkalemia, but it may facilitate more opportunity to optimize RAASi use in patients with CKD and/or cardiovascular disease.

Disclosures

Dr. Weir reports personal fees from Relypsa, personal fees from ZS Pharma during the conduct of the study, personal fees from Akebia, personal fees from Janssen, personal fees from AstraZeneca, personal fees from Amgen, personal fees from MSD, personal fees from AbbVie, personal fees from Novartis, personal fees from Boston Scientific, and personal fees from Sandoz outside the submitted work.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study,” on pages 798–809.

  • Copyright © 2019 by the American Society of Nephrology

References

  1. ↵
    1. Einhorn LM,
    2. Zhan M,
    3. Hsu VD,
    4. Walker LD,
    5. Moen MF,
    6. Seliger SL,
    7. Weir MR,
    8. Fink JC
    : The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169: 1156–1162, 2009pmid:19546417
    OpenUrlCrossRefPubMed
  2. ↵
    1. Noori N,
    2. Kalantar-Zadeh K,
    3. Kovesdy CP,
    4. Murali SB,
    5. Bross R,
    6. Nissenson AR,
    7. Kopple JD
    : Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis 56: 338–347, 2010pmid:20580474
    OpenUrlCrossRefPubMed
  3. ↵
    1. Harel Z,
    2. Harel S,
    3. Shah PS,
    4. Wald R,
    5. Perl J,
    6. Bell CM
    : Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: A systematic review. Am J Med 126: 264.e9–264.e24, 2013
    OpenUrlCrossRefPubMed
  4. ↵
    1. Weir MR,
    2. Bakris GL,
    3. Bushinsky DA,
    4. Mayo MR,
    5. Garza D,
    6. Stasiv Y,
    7. Wittes J,
    8. Christ-Schmidt H,
    9. Berman L,
    10. Pitt B; OPAL-HK Investigators
    : Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372: 211–221, 2015pmid:25415805
    OpenUrlCrossRefPubMed
  5. ↵
    1. Pergola PE,
    2. Roger SD,
    3. Lerma EV,
    4. Butler J,
    5. von Haehling S,
    6. Adler SH,
    7. Zhao J,
    8. Singh B,
    9. Lavin PT,
    10. McCullough PA,
    11. Kosiborod M,
    12. Packham DK
    1. Spinowitz BS
    , Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK; ZS-005 Study Investigators: Sodium zirconium cyclosilicate among individuals with hyperkalemia: A 12-month phase 3 study. Clin J Am Soc Nephrol 14: 798–809, 2019
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Brenner BM,
    2. Cooper ME,
    3. de Zeeuw D,
    4. Keane WF,
    5. Mitch WE,
    6. Parving HH,
    7. Remuzzi G,
    8. Snapinn SM,
    9. Zhang Z,
    10. Shahinfar S; RENAAL Study Investigators
    : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001pmid:11565518
    OpenUrlCrossRefPubMed
  7. ↵
    1. Lewis EJ,
    2. Hunsicker LG,
    3. Clarke WR,
    4. Berl T,
    5. Pohl MA,
    6. Lewis JB,
    7. Ritz E,
    8. Atkins RC,
    9. Rohde R,
    10. Raz I; Collaborative Study Group
    : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860, 2001pmid:11565517
    OpenUrlCrossRefPubMed
  8. ↵
    1. Pitt B,
    2. Zannad F,
    3. Remme WJ,
    4. Cody R,
    5. Castaigne A,
    6. Perez A,
    7. Palensky J,
    8. Wittes J; Randomized Aldactone Evaluation Study Investigators
    : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717, 1999pmid:10471456
    OpenUrlCrossRefPubMed
  9. ↵
    1. Vardeny O,
    2. Claggett B,
    3. Anand I,
    4. Rossignol P,
    5. Desai AS,
    6. Zannad F,
    7. Pitt B,
    8. Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators
    : Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7: 573–579, 2014pmid:24812304
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Pitt B,
    2. Anker SD,
    3. Bushinsky DA,
    4. Kitzman DW,
    5. Zannad F,
    6. Huang IZ; PEARL-HF Investigators
    : Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32: 820–828, 2011pmid:21208974
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 14 (6)
Clinical Journal of the American Society of Nephrology
Vol. 14, Issue 6
June 07, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Therapeutic Potential of Newer Drugs for Treating Hyperkalemia
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Therapeutic Potential of Newer Drugs for Treating Hyperkalemia
Matthew R. Weir
CJASN Jun 2019, 14 (6) 787-788; DOI: 10.2215/CJN.04750419

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Therapeutic Potential of Newer Drugs for Treating Hyperkalemia
Matthew R. Weir
CJASN Jun 2019, 14 (6) 787-788; DOI: 10.2215/CJN.04750419
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Time to Procurement and Post-Kidney Transplant Outcomes
  • Recurrent Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment
  • Postkidney Transplant Care and Health Outcomes of US Veterans
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia
  • PubMed
  • Google Scholar

Keywords

  • hyperkalemia
  • chronic kidney disease
  • renin angiotensin aldosterone-system inhibitors
  • Potassium
  • risk factors

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire